

M Juliana Mcelrath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8271188/publications.pdf>

Version: 2024-02-01

148
papers

18,231
citations

30070

54
h-index

15266

126
g-index

161
all docs

161
docs citations

161
times ranked

21571
citing authors

#	ARTICLE	IF	CITATIONS
1	MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data. <i>Genome Biology</i> , 2015, 16, 278.	8.8	2,047
2	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	27.0	1,699
3	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. <i>Lancet, The</i> , 2008, 372, 1881-1893.	13.7	1,560
4	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a caseâ€“cohort analysis. <i>Lancet, The</i> , 2008, 372, 1894-1905.	13.7	670
5	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	27.0	518
6	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	12.6	468
7	Setting the stage: host invasion by HIV. <i>Nature Reviews Immunology</i> , 2008, 8, 447-457.	22.7	456
8	Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1. <i>Immunity</i> , 2007, 26, 257-270.	14.3	427
9	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	27.0	418
10	Origin and differentiation of human memory CD8 T cells after vaccination. <i>Nature</i> , 2017, 552, 362-367.	27.8	412
11	HIV-1 Integration Landscape during Latent and Active Infection. <i>Cell</i> , 2015, 160, 420-432.	28.9	393
12	Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> , 2020, 53, 98-105.e5.	14.3	376
13	A Blueprint for HIV Vaccine Discovery. <i>Cell Host and Microbe</i> , 2012, 12, 396-407.	11.0	348
14	Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. <i>Cell</i> , 2015, 163, 988-998.	28.9	326
15	CXCL13 is a plasma biomarker of germinal center activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2702-2707.	7.1	322
16	Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. <i>Cell Reports Medicine</i> , 2021, 2, 100354.	6.5	316
17	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	27.0	270
18	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	13.7	269

#	ARTICLE	IF	CITATIONS
19	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectors Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	7.4	266
20	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. <i>Science</i> , 2016, 352, 997-1001.	12.6	263
21	Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination. <i>Immunity</i> , 2010, 33, 542-554.	14.3	239
22	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	17.5	232
23	Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. <i>Journal of Immunological Methods</i> , 2007, 323, 39-54.	1.4	223
24	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. <i>Nature Medicine</i> , 2011, 17, 366-371.	30.7	220
25	Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. <i>Journal of Immunological Methods</i> , 2007, 322, 57-69.	1.4	206
26	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
27	COVID-19 and the Path to Immunity. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1279.	7.4	156
28	HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women. <i>Journal of Experimental Medicine</i> , 1997, 185, 293-304.	8.5	151
29	Effect of Combination Antiretroviral Therapy on T Cell Immunity in Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2000, 181, 121-131.	4.0	148
30	Merck Ad5/HIV induces broad innate immune activation that predicts CD8 ⁺ T-cell responses but is attenuated by preexisting Ad5 immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3503-12.	7.1	148
31	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120 MF59 in Adults. <i>New England Journal of Medicine</i> , 2021, 384, 1089-1100.	27.0	144
32	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	2.5	131
33	Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. <i>Journal of Clinical Investigation</i> , 2012, 122, 359-367.	8.2	127
34	Distinct activation thresholds of human conventional and innate-like memory T cells. <i>JCI Insight</i> , 2016, 1, .	5.0	116
35	Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. <i>Journal of Experimental Medicine</i> , 2017, 214, 2139-2152.	8.5	106
36	A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	105

#	ARTICLE	IF	CITATIONS
37	An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus. <i>Immunity</i> , 2018, 48, 799-811.e9.	14.3	104
38	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	8.2	99
39	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , 2021, 36, 109353.	6.4	95
40	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	8.2	95
41	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV</i> , 2018, 5, e366-e378.	4.7	86
42	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	14.3	85
43	Long-term Effect of Depot Medroxyprogesterone Acetate on Vaginal Microbiota, Epithelial Thickness and HIV Target Cells. <i>Journal of Infectious Diseases</i> , 2014, 210, 651-655.	4.0	82
44	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	4.7	81
45	Vaccine-Induced Gag-Specific T Cells Are Associated With Reduced Viremia After HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1231-1239.	4.0	73
46	Optimizing Viable Leukocyte Sampling from the Female Genital Tract for Clinical Trials: An International Multi-Site Study. <i>PLoS ONE</i> , 2014, 9, e85675.	2.5	73
47	Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2014, 210, 99-110.	4.0	73
48	A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. <i>Journal of Infectious Diseases</i> , 2011, 203, 1165-1173.	4.0	71
49	CXCR3 enables recruitment and site-specific bystander activation of memory CD8+ T cells. <i>Nature Communications</i> , 2019, 10, 4987.	12.8	68
50	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
51	Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1713-1723.	1.1	60
52	Challenges and responses in human vaccine development. <i>Current Opinion in Immunology</i> , 2014, 28, 18-26.	5.5	60
53	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1376-1385.	4.0	59
54	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV</i> , 2020, 7, e688-e698.	4.7	58

#	ARTICLE	IF	CITATIONS
55	Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. <i>Journal of Virology</i> , 2014, 88, 8242-8255.	3.4	55
56	HIV-DNA Priming Alters T Cell Responses to HIV-Adenovirus Vaccine Even When Responses to DNA Are Undetectable. <i>Journal of Immunology</i> , 2011, 187, 3391-3401.	0.8	54
57	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in <i>Mycobacterium tuberculosis</i> -uninfected adolescents in Cape Town, South Africa. <i>EClinicalMedicine</i> , 2020, 21, 100313.	7.1	52
58	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , 2015, 21, 1139-1141.	30.7	50
59	Use of adenovirus type-5 vectored vaccines: a cautionary tale. <i>Lancet, The</i> , 2020, 396, e68-e69.	13.7	50
60	HIV-1 Single-Stranded RNA Induces CXCL13 Secretion in Human Monocytes via TLR7 Activation and Plasmacytoid Dendritic Cell-Derived Type I IFN. <i>Journal of Immunology</i> , 2015, 194, 2769-2775.	0.8	49
61	BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults. <i>JCI Insight</i> , 2019, 4, .	5.0	48
62	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	12.4	47
63	Plasma Cytokine Levels and Risk of HIV Type 1 (HIV-1) Transmission and Acquisition: A Nested Case-Control Study Among HIV-1 Serodiscordant Couples. <i>Journal of Infectious Diseases</i> , 2015, 211, 1451-1460.	4.0	47
64	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	6.1	47
65	Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054). <i>PLoS ONE</i> , 2010, 5, e13579.	2.5	47
66	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	46
67	Progress in HIV-1 vaccine development. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	3.8	45
68	Controlled Human Malaria Infection Leads to Long-Lasting Changes in Innate and Innate-like Lymphocyte Populations. <i>Journal of Immunology</i> , 2017, 199, 107-118.	0.8	45
69	OMIP-014: Validated multifunctional characterization of antigen-specific human T cells by intracellular cytokine staining. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 1019-1021.	1.5	44
70	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. <i>Scientific Reports</i> , 2021, 11, 23921.	3.3	44
71	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV, the</i> , 2019, 6, e737-e749.	4.7	43
72	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	3.4	42

#	ARTICLE	IF	CITATIONS
73	Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials. <i>PLoS ONE</i> , 2016, 11, e0147812.	2.5	42
74	HIV-1 Vaccine-Induced T-Cell Responses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1. <i>PLoS Pathogens</i> , 2013, 9, e1003404.	4.7	39
75	Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. <i>PLoS ONE</i> , 2018, 13, e0202753.	2.5	39
76	Mucosal effects of tenofovir 1% gel. <i>ELife</i> , 2015, 4, .	6.0	37
77	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. <i>PLoS ONE</i> , 2014, 9, e101863.	2.5	36
78	OMIP-025: Evaluation of human T and NK cell responses including memory and follicular helper phenotype by intracellular cytokine staining. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 289-292.	1.5	36
79	Ex Vivo Comparison of Microbicide Efficacies for Preventing HIV-1 Genomic Integration in Intraepithelial Vaginal Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 763-772.	3.2	35
80	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. <i>Tuberculosis</i> , 2015, 95, 713-721.	1.9	35
81	RTS,S/AS01E Malaria Vaccine Induces Memory and Polyfunctional T Cell Responses in a Pediatric African Phase III Trial. <i>Frontiers in Immunology</i> , 2017, 8, 1008.	4.8	34
82	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. <i>PLoS Medicine</i> , 2021, 18, e1003813.	8.4	34
83	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 ⁺ T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , 2017, 24, .	3.1	33
84	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	4.0	32
85	MRKA5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load. <i>PLoS ONE</i> , 2012, 7, e43396.	2.5	30
86	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017, 12, e0179597.	2.5	29
87	Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083. <i>Journal of Infectious Diseases</i> , 2016, 213, 541-550.	4.0	28
88	The Inner Foreskin of Healthy Males at Risk of HIV Infection Harbors Epithelial CD4 ⁺ CCR5 ⁺ Cells and Has Features of an Inflamed Epidermal Barrier. <i>PLoS ONE</i> , 2014, 9, e108954.	2.5	27
89	T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents. <i>Journal of Immunology</i> , 2015, 195, 4595-4603.	0.8	27
90	Adjuvants. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 278-284.	3.8	27

#	ARTICLE	IF	CITATIONS
91	Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. <i>Nature Communications</i> , 2019, 10, 863.	12.8	27
92	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	8.4	27
93	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. <i>Journal of Clinical Investigation</i> , 2019, 129, 4769-4785.	8.2	27
94	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	2.5	27
95	Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial. <i>PLoS Medicine</i> , 2022, 19, e1003865.	8.4	27
96	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	3.4	26
97	Identification and visualization of multidimensional antigen-specific T cell populations in polychromatic cytometry data. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2015, 87, 675-682.	1.5	25
98	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	4.8	25
99	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , 2020, 5, .	5.0	25
100	HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 4843-4856.	8.2	25
101	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon- β Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study. <i>PLoS ONE</i> , 2014, 9, e108631.	2.5	23
102	Optimization of a whole blood phenotyping assay for enumeration of peripheral blood leukocyte populations in multicenter clinical trials. <i>Journal of Immunological Methods</i> , 2014, 411, 23-36.	1.4	23
103	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	2.5	23
104	Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal. <i>Journal of Immunological Methods</i> , 2014, 409, 9-20.	1.4	20
105	Rank-based two-sample tests for paired data with missing values. <i>Biostatistics</i> , 2018, 19, 281-294.	1.5	19
106	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	4.7	19
107	Antigenic competition in CD4 ⁺ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	18
108	Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release. <i>Molecular Systems Biology</i> , 2021, 17, e10426.	7.2	18

#	ARTICLE	IF	CITATIONS
109	Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. <i>Journal of AIDS & Clinical Research</i> , 2015, 06, .	0.5	17
110	HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , 2020, 10, 2093.	3.3	17
111	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	17
112	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16
113	Whole genome sequencing of extreme phenotypes identifies variants in CD101 and UBE2V1 associated with increased risk of sexually acquired HIV-1. <i>PLoS Pathogens</i> , 2017, 13, e1006703.	4.7	16
114	Immune Responses to HIV Vaccines and Potential Impact on Control of Acute HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2010, 202, S323-S326.	4.0	15
115	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	5.8	15
116	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , 2016, 17, 57-65.	5.4	14
117	Cryopreservation of human mucosal tissues. <i>PLoS ONE</i> , 2018, 13, e0200653.	2.5	14
118	OMIP-056: Evaluation of Human Conventional T Cells, Donor-Independent T Cells, and NK Cells Including Memory Phenotype by Intracellular Cytokine Staining. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 722-725.	1.5	14
119	Cryopreservation of Human Mucosal Leukocytes. <i>PLoS ONE</i> , 2016, 11, e0156293.	2.5	14
120	Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate. <i>Clinical and Translational Immunology</i> , 2022, 11, e1360.	3.8	14
121	Standing Guard at the Mucosa. <i>Immunity</i> , 2011, 34, 146-148.	14.3	13
122	Measuring inhibition of HIV replication by ex vivo CD8+ T cells. <i>Journal of Immunological Methods</i> , 2014, 404, 71-80.	1.4	12
123	Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency. <i>Science Translational Medicine</i> , 2022, 14, eabg8070.	12.4	12
124	Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials. <i>Vaccine</i> , 2018, 36, 5671-5677.	3.8	11
125	Analysis of the HIV Vaccine Trials Network 702 Phase 2b/3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	4.0	11
126	Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. <i>Cell Reports Medicine</i> , 2020, 1, 100096.	6.5	10

#	ARTICLE	IF	CITATIONS
127	Distinct populations of antigen specific tissue resident CD8 T cells in human cervix mucosa. JCI Insight, 2021, 6, .	5.0	10
128	Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice. Journal of Virology, 2017, 91, .	3.4	9
129	Mechanisms of Endogenous HIV-1 Reactivation by Endocervical Epithelial Cells. Journal of Virology, 2020, 94, .	3.4	9
130	Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies. Journal of Immunological Methods, 2021, 488, 112901.	1.4	9
131	Systems analysis of immune responses to attenuated P. falciparum malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity. PLoS Pathogens, 2022, 18, e1010282.	4.7	9
132	Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. Viruses, 2021, 13, 1472.	3.3	8
133	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Medicine, 2020, 17, e1003117.	8.4	8
134	Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period. Journal of Infectious Diseases, 2019, 219, 1755-1765.	4.0	7
135	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines, 2021, 6, 56.	6.0	7
136	Activated PD-1+ CD4+ T cells represent a short-lived part of the viral reservoir and predict poor immunologic recovery upon initiation of ART. Aids, 2020, 34, 197-202.	2.2	6
137	Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection. PLoS ONE, 2016, 11, e0160487.	2.5	6
138	Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched caseâ€“control study. ELife, 2022, 11, .	6.0	4
139	In Situ Staining and Laser Capture Microdissection of Lymph Node Residing SIV Gag-Specific CD8+ T cellsâ€“A Tool to Interrogate a Functional Immune Response Ex Vivo. PLoS ONE, 2016, 11, e0149907.	2.5	3
140	Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4+ T Cells That Correlated with Reduced Risk of Infection in RV144 Trial. Journal of Immunology, 2022, 209, 526-534.	0.8	3
141	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. Vaccine, 2015, 33, 749-752.	3.8	2
142	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. Vaccine, 2021, 39, 4641-4650.	3.8	1
143	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. PLoS Pathogens, 2021, 17, e1010016.	4.7	1
144	Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. Science Advances, 2022, 8, eabm3948.	10.3	1

#	ARTICLE	IF	CITATIONS
145	T-cell Responses Targeting HIV Env V2 in Natural Infection: Implications for RV144 Vaccine Recipients. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A179-A179.	1.1	0
146	Response to Guo et al.'s Letter to the Editor. <i>Biostatistics</i> , 2019, 20, 363-365.	1.5	0
147	Rapid Collection of Human Rectal Secretions Using OriCol Devices Is Suitable for Measurement of Mucosal Ig without Blood Contamination. <i>Journal of Immunology</i> , 2020, 205, 2312-2320.	0.8	0
148	HIV-1 Nucleic Acids Identify Rectal HIV Exposures in Self-Collected Rectal Swabs, Whereas Y-Chromosome Single Tandem Repeat Mixtures Are Not Reliable Biomarkers of Condomless Receptive Anal Intercourse. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 138-148.	2.1	0